OBJECTIVES: In the present study, we investigated the effects of statins on serum levels of soluble CD40 ligand (sCD40L) in patients with familial hypercholesterolemia (FH). BACKGROUND: Atherosclerotic disease seems to involve inflammatory and immunologic mechanisms, and sCD40L has recently been identified as one of the key players in the atherosclerotic process. HMG-Co A reductase inhibitors, statins, have been recognized as immunomodulators and reduce cardiovascular events and mortality, but the effects of statins on sCD40L has not been clarified. METHODS: In a randomized, double-blind, clinical trial, as part of the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) trial, 110 patients with FH were givenatorvastatin 80 mg/daily (n = 57) or simvastatin 40 mg/daily (n = 53) for two years. RESULTS: Our main findings were: 1) at baseline patients with FH had significantly higher (approximately 27-fold) serum levels of sCD40L than healthy controls; 2) statin therapy markedly decreased serum levels of sCD40L (approximately 40% reduction); 3) this decrease in sCD40L was found during both "aggressive" (i.e., atorvastatin) and "conventional" (i.e., simvastatin) statin therapy and was not correlated with the degree of reduction in cholesterol levels. CONCLUSIONS: Our findings may suggest enhanced CD40L-CD40 interaction in FH and that this inflammatory response may be downregulated by statins.
RCT Entities:
OBJECTIVES: In the present study, we investigated the effects of statins on serum levels of soluble CD40 ligand (sCD40L) in patients with familial hypercholesterolemia (FH). BACKGROUND:Atherosclerotic disease seems to involve inflammatory and immunologic mechanisms, and sCD40L has recently been identified as one of the key players in the atherosclerotic process. HMG-Co A reductase inhibitors, statins, have been recognized as immunomodulators and reduce cardiovascular events and mortality, but the effects of statins on sCD40L has not been clarified. METHODS: In a randomized, double-blind, clinical trial, as part of the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) trial, 110 patients with FH were given atorvastatin 80 mg/daily (n = 57) or simvastatin 40 mg/daily (n = 53) for two years. RESULTS: Our main findings were: 1) at baseline patients with FH had significantly higher (approximately 27-fold) serum levels of sCD40L than healthy controls; 2) statin therapy markedly decreased serum levels of sCD40L (approximately 40% reduction); 3) this decrease in sCD40L was found during both "aggressive" (i.e., atorvastatin) and "conventional" (i.e., simvastatin) statin therapy and was not correlated with the degree of reduction in cholesterol levels. CONCLUSIONS: Our findings may suggest enhanced CD40L-CD40 interaction in FH and that this inflammatory response may be downregulated by statins.
Authors: Samar M Hammad; Jean-Philip Truman; Mohammed M Al Gadban; Kent J Smith; Waleed O Twal; Mark B Hamner Journal: Neurobiol Lipids Date: 2012-03-22
Authors: Ilkay Tugba Unek; Firat Bayraktar; Dilek Solmaz; Hulya Ellidokuz; Ali Riza Sisman; Faize Yuksel; Sena Yesil Journal: Clin Med Res Date: 2010-07
Authors: Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard Journal: Nat Rev Rheumatol Date: 2018-03-21 Impact factor: 20.543
Authors: Karen Y Stokes; Leshanna Calahan; Candiss M Hamric; Janice M Russell; D Neil Granger Journal: Am J Physiol Heart Circ Physiol Date: 2008-12-26 Impact factor: 4.733
Authors: Changyi Chen; Hong Chai; Xinwen Wang; Jun Jiang; Md Saha Jamaluddin; Dan Liao; Yuqing Zhang; Hao Wang; Uddalak Bharadwaj; Sheng Zhang; Min Li; Peter Lin; Qizhi Yao Journal: Blood Date: 2008-07-24 Impact factor: 22.113
Authors: John F Keaney; Izabella Lipinska; Martin G Larson; Josée Dupuis; Jane E Freedman; Naomi M Hamburg; Joseph M Massaro; Jian Rong; Patrice Sutherland; Joseph A Vita; Ramachandran S Vasan; Emelia J Benjamin Journal: Am Heart J Date: 2008-10-02 Impact factor: 4.749